MOONLAKE IMMUNOTHERAPEUTICS Financing Cash Flow
MOONLAKE IMMUNOTHERAPEUTICS (MLTX) reported Financing Cash Flow of $265.27 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-10
- MOONLAKE IMMUNOTHERAPEUTICS net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $234.62M.
- MOONLAKE IMMUNOTHERAPEUTICS net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $30.64M, a 58.09% decline year-over-year.
- MOONLAKE IMMUNOTHERAPEUTICS net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $72.39M, a 47843.71% increase year-over-year.
- MOONLAKE IMMUNOTHERAPEUTICS net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $480.00K, a 162.30% increase year-over-year.
- MOONLAKE IMMUNOTHERAPEUTICS net cash provided by (used in) financing activities for fiscal 2025 was $146.00M, a 184.53% increase from fiscal 2024.
- MOONLAKE IMMUNOTHERAPEUTICS net cash provided by (used in) financing activities for fiscal 2024 was $51.31M, a 89.30% decline from fiscal 2023.
- MOONLAKE IMMUNOTHERAPEUTICS net cash provided by (used in) financing activities for fiscal 2023 was $479.70M, a 300.78% increase from fiscal 2022.
- MOONLAKE IMMUNOTHERAPEUTICS net cash provided by (used in) financing activities for fiscal 2022 was $119.69M.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 3 month as first filed | Net Cash Provided by (Used in) Financing Activities 5 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 6 month as first filed | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 9 month as first filed | Net Cash Provided by (Used in) Financing Activities 10 month | Net Cash Provided by (Used in) Financing Activities 12 month | Net Cash Provided by (Used in) Financing Activities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $234.62M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $265.27M 10-Q · filed 2026-08-10 | $337.66M derived: sum of 3 quarters · filed 2026-08-10 | $338.14M derived: sum of 4 quarters · filed 2026-08-10 | ||||||
| 2026-03-31 | $30.64M 10-Q · filed 2026-05-11 | $103.04M derived: sum of 2 quarters · filed 2026-05-11 | $103.52M derived: sum of 3 quarters · filed 2026-05-11 | $103.52M derived: sum of 4 quarters · filed 2026-08-10 | ||||||
| 2025-12-31 | $72.39M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $72.88M derived: sum of 2 quarters · filed 2026-02-25 | $72.88M derived: sum of 3 quarters · filed 2026-08-10 | $146.00M 10-K · filed 2026-02-25 | ||||||
| 2025-09-30 | $480.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $480.00K derived: sum of 2 quarters · filed 2026-08-10 | $73.60M 10-Q · filed 2025-11-05 | $73.75M derived: sum of 4 quarters · filed 2026-08-10 | ||||||
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $73.12M 10-Q · filed 2026-08-10 | $73.27M derived: sum of 3 quarters · filed 2026-08-10 | $73.46M derived: sum of 4 quarters · filed 2026-08-10 | ||||||
| 2025-03-31 | $73.12M 10-Q · filed 2026-05-11 | $73.27M derived: sum of 2 quarters · filed 2026-05-11 | $73.46M derived: sum of 3 quarters · filed 2026-05-11 | $73.46M derived: sum of 4 quarters · filed 2026-05-11 | ||||||
| 2024-12-31 | $151.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $334.00K derived: sum of 2 quarters · filed 2026-02-25 | $334.00K derived: sum of 3 quarters · filed 2026-02-25 | $51.31M 10-K · filed 2026-02-25 | $51.31M 10-K · filed 2025-02-26 | |||||
| 2024-09-30 | $183.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $183.00K derived: sum of 2 quarters · filed 2025-11-05 | $51.16M 10-Q · filed 2025-11-05 | $51.16M 10-Q · filed 2024-11-07 | $79.58M derived: sum of 4 quarters · filed 2026-02-25 | |||||
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $50.98M 10-Q · filed 2025-08-05 | $50.98M 10-Q · filed 2024-08-07 | $79.39M derived: sum of 3 quarters · filed 2026-02-25 | $79.39M derived: sum of 4 quarters · filed 2026-02-25 | |||||
| 2024-03-31 | $50.98M 10-Q · filed 2025-05-12 | $50.98M 10-Q · filed 2024-05-07 | $79.39M derived: sum of 2 quarters · filed 2026-02-25 | $79.39M derived: sum of 3 quarters · filed 2026-02-25 | $530.68M derived: sum of 4 quarters · filed 2026-02-25 | |||||
| 2023-12-31 | $28.42M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $28.42M derived: sum of 2 quarters · filed 2026-02-25 | $479.70M derived: sum of 3 quarters · filed 2026-02-25 | $479.70M 10-K · filed 2026-02-25 | $479.70M 10-K · filed 2024-02-29 | |||||
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $451.29M derived: sum of 2 quarters · filed 2024-11-07 | $451.29M 10-Q · filed 2024-11-07 | $451.29M derived: sum of 4 quarters · filed 2025-02-26 | ||||||
| 2023-06-30 | $451.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $451.29M 10-Q · filed 2024-08-07 | $451.29M derived: sum of 3 quarters · filed 2025-02-26 | $451.29M derived: sum of 4 quarters · filed 2025-02-26 | ||||||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-07 | $3.79K derived: sum of 2 quarters · filed 2025-02-26 | $3.79K derived: sum of 3 quarters · filed 2025-02-26 | $104.69M derived: sum of 4 quarters · filed 2025-02-26 | ||||||
| 2022-12-31 | $3.79K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $3.79K derived: sum of 2 quarters · filed 2025-02-26 | $104.69M derived: sum of 3 quarters · filed 2025-02-26 | $119.69M 10-K · filed 2025-02-26 | ||||||
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $104.69M derived: sum of 2 quarters · filed 2023-11-14 | $119.69M 10-Q · filed 2023-11-14 | $91.37M derived: sum of 4 quarters · filed 2023-11-14 | ||||||
| 2022-06-30 | $104.69M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $119.69M 10-Q · filed 2023-08-10 | $91.37M derived: sum of 3 quarters · filed 2023-08-10 | $91.87M derived: sum of 4 quarters · filed 2023-08-10 | ||||||
| 2022-03-31 | $15.00M 10-Q · filed 2023-05-11 | $150.00K 10-Q · filed 2022-05-16 | -$13.32M derived: sum of 2 quarters · filed 2023-05-11 | -$12.82M derived: sum of 3 quarters · filed 2023-05-11 | $15.00M derived: sum of 4 quarters · filed 2023-05-11 | |||||
| 2021-12-31 | -$28.32M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-17 | -$27.82M derived: sum of 2 quarters · filed 2022-11-14 | $0.00 derived: sum of 3 quarters · filed 2022-11-14 | $43.26M 10-K · filed 2023-03-20 | -$58.06K 10-K · filed 2022-02-17 | |||||
| 2021-09-30 | $498.33K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $28.32M derived: sum of 2 quarters · filed 2022-11-14 | $28.26M 10-Q · filed 2022-11-14 | -$58.06K 10-Q · filed 2021-11-12 | ||||||
| 2021-06-30 | $27.82M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | $27.77M 10-Q · filed 2022-08-12 | -$58.06K 10-Q · filed 2021-08-16 | |||||||
| 2021-03-31 | -$58.06K 10-Q · filed 2022-05-16 | |||||||||
| 2020-12-31 | $116.65M 10-K · filed 2022-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |